A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging

Stopped early · Phase 2

Conditions studied: Cardiovascular Disease, Ischemic Heart Disease

In brief

The primary purpose of this study is to determine the optimal time for myocardial perfusion imaging with Technetium Tc99m Sestamibi following the administration of BMS068645. The safety of BMS068645 will also be studied.

Key facts

Study ID

NCT00162071

Run by

Forest Laboratories

People needed

20

Starts

2005-07-01

Last updated by the study team

2017-02-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older
• Have known or suspected heart disease
• Have undergone a clinically indicated SPECT MPI study with adenosine in the last 24 hours to 14 days.
• Weigh between 88 and 250 lbs.

You may not qualify if…

• Allergic reaction to Technetium Tc99m Sestamibi or any of its components
• History of asthma or lung disease
• Ingestion of caffeinated substances within 12 hours prior to the study

Where it is running

• Local Institution — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.